Independent and epistatic effects of variants in VPS10-d receptors on Alzheimer disease risk and processing of the amyloid precursor protein (APP)
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Genetic variants in the sortilin-related receptor (SORL1) and the sortilin-related vacuolar protein sorting 10 (VPS10) domain-containing receptor 1 (SORCS1) are associated with increased risk of Alzheimer's disease (AD), declining cognitive function and altered amyloid precursor protein (APP) processing. We explored whether other members of the (VPS10) domain-containing receptor protein family (the sortilin-related VPS10 domain-containing receptors 2 and 3 (SORCS2 and SORCS3) and sortilin (SORT1)) would have similar effects either independently or together. We conducted the analyses in a large Caucasian case control data set (n=11,840 cases, 10,931 controls) to determine the associations between single nucleotide polymorphisms (SNPs) in all the five homologous genes and AD risk. Evidence for interactions between SNPs in the five VPS10 domain receptor family genes was determined in epistatic statistical models. We also compared expression levels of SORCS2, SORCS3 and SORT1 in AD and control brains using microarray gene expression analyses and assessed the effects of these genes on γ-secretase processing of APP. Several SNPs in SORL1, SORCS1, SORCS2 and SORCS3 were associated with AD. In addition, four specific linkage disequilibrium blocks in SORCS1, SORCS2 and SORCS3 showed additive epistatic effects on the risk of AD (P≤0.0006). SORCS3, but not SORCS2 or SORT1, showed reduced expression in AD compared with control brains, but knockdown of all the three genes using short hairpin RNAs in HEK293 cells caused a significant threefold increase in APP processing (from P<0.001 to P<0.05). These findings indicate that in addition to SORL1 and SORCS1, variants in other members of the VPS10 domain receptor family (that is, SORCS1, SORCS2, SORCS3) are associated with AD risk and alter APP processing. More importantly, the results indicate that variants within these genes have epistatic effects on AD risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Initiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997
Naj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901 · cited 4×
“HapMap2-imputed genotypic data for single nucleotide polymorphisms (SNPs) in SORCS1 (n1⁄4 648), SORCS2 (n1⁄4 740), SORCS3 (n1⁄4 742), SORL1 (n1⁄4 160) and SORT1 (n1⁄4 40) was obtained from the previously published genome-wide association study.(23) The SNPs assessed included both intronic and exonic SNPs.”
MethodInfluentialSelf-citationAdjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix
Li, J., & Ji, L. (2005) · Heredity · doi:10.1038/sj.hdy.6800717 · Cited by 1,458 · cited 4×
“As described above, LD between the markers was taken into account applying the algorithm by Li and Ji.28 Statistical analysis for the gene expression and quantitative RT–PCR data.”
MethodInfluentialGenome-wide Analysis of Genetic Loci Associated With Alzheimer Disease
Seshadri, S. (2010) · JAMA · doi:10.1001/jama.2010.574 · Cited by 1,219
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease
Rogaeva, E., Meng, Y., Lee, J. H., Gu, Y., Kawarai, T., Zou, F., Katayama, T., Baldwin, C. T., Cheng, R., Hasegawa, H., et al. (2007) · Nature Genetics · doi:10.1038/ng1943 · Cited by 1,167 · cited 9×
“and is located 6 kb from SNP 25, which is part of one of the two SORL1 clusters that have been repeatedly associated with AD in different ethnic groups.(3,18) The SNPs in SORCS1, SORCS2 and SORCS3 were close, but not statistically significant.”
BackgroundResultInfluentialSelf-citationGenetic Control of Human Brain Transcript Expression in Alzheimer Disease
Webster, J. A., Gibbs, J. R., Clarke, J., Ray, M., Zhang, W., Holmans, P., Rohrer, K., Zhao, A., Marlowe, L., Kaleem, M., et al. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2009.03.011 · Cited by 304 · cited 1×
“edu/myers/ ).(30) We did not find a significant difference between AD and controls in the expression levels of SORCS2 or SORT1 (Figures 2b and c).”
BackgroundJacobsen, L., Madsen, P., Moestrup, S. K., Lund, A. H., Tommerup, N., Nykjær, A., Sottrup-Jensen, L., Gliemann, J., & Petersen, C. M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.49.31379 · Cited by 253
Quantitative modelling of amyloidogenic processing and its influence by SORLA in Alzheimer's disease
Schmidt, V., Baum, K., Lao, A., Rateitschak, K., Schmitz, Y., Teichmann, A., Wiesner, B., Petersen, C. M., Nykjaer, A., Wolf, J., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.352 · Cited by 75
Cited by
Alzheimer’s Disease Genetics: From the Bench to the Clinic
Karch, C. M., Cruchaga, C., & Goate, A. M. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.041 · Cited by 473
Retromer in Alzheimer disease, Parkinson disease and other neurological disorders
Small, S. A., & Petsko, G. A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3896 · Cited by 227
Multi-trait analysis for genome-wide association study of five psychiatric disorders
Wu, Y., Cao, H., Baranova, A., Huang, H., Li, S., Cai, L., Rao, S., Dai, M., Xie, M., Dou, Y., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00902-6 · Cited by 218
Young, J. E., Fong, L. K., Frankowski, H., Petsko, G. A., Small, S. A., & Goldstein, L. S. B. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.01.031 · Cited by 110
Urinary metabolic phenotyping for Alzheimer’s disease
Kurbatova, N., Garg, M., Whiley, L., Chekmeneva, E., Jiménez, B., Gómez-Romero, M., Pearce, J., Kimhofer, T., D’Hondt, E., Soininen, H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-78031-9 · Cited by 44
Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease
Salasova, A., Monti, G., Andersen, O. M., & Nykjaer, A. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00576-2 · Cited by 42
Botchway, B. O., Okoye, F. C., Chen, Y., Arthur, W. E., & Fang, M. (2022) · Aging and disease · doi:10.14336/ad.2021.0616 · Cited by 32
“More intriguingly, previous studies also found no link between this genetic mutation and AD [63, 64].”
BackgroundImpact of Genetic Risk Factors for Alzheimer’s Disease on Brain Glucose Metabolism
Cho, S., Lee, H., & Seo, J. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02297-x · Cited by 25
Metadata
- Authors
- Reitz, C., Tosto, G., Vardarajan, B., Rogaeva, E., Ghani, M., Rogers, R. S., Conrad, C., Haines, J. L., Pericak-Vance, M. A., Fallin, M. D., Foroud, T., Farrer, L. A., Schellenberg, G. D., George-Hyslop, P. S., Mayeux, R., & the Alzheimer’s Disease Genetics Consortium (ADGC)
- Venue
- Translational Psychiatry
- Published
- 2013-05-14
- Volume
- 3
- Issue
- 5
- Pages
- e256-e256
- ISSN
- 2158-3188 (ISSN-L)
- OpenAlex
- W1969013845
- Cited by
- 85
- References
- 11
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.